TY  - JOUR
AU  - Maass, Fabian
AU  - Canaslan, Sezgi
AU  - van Riesen, Christoph
AU  - Hermann, Peter
AU  - Schmitz, Matthias
AU  - Schulte, Claudia
AU  - Brockmann, Kathrin
AU  - Synofzik, Matthis
AU  - Bähr, Mathias
AU  - Zerr, Inga
TI  - Myelin basic protein and TREM2 quantification in the CSF of patients with Multiple System Atrophy and other Parkinsonian conditions.
JO  - Journal of neurology
VL  - 272
IS  - 1
SN  - 0367-004X
CY  - Heidelberg
PB  - Springer
M1  - DZNE-2024-01412
SP  - 52
PY  - 2025
AB  - It is well known that myelin disruption and neuroinflammation are early and distinct pathological hallmarks in multiple system atrophy (MSA) as well as in idiopathic Parkinson's disease and in other atypical Parkinsonian syndromes. The objective of this study was to assess the value of non-neuronal biomarker candidates that reflect myelin disruption and neuroinflammation.Myelin basic protein (MBP) and the soluble form of TREM2 were quantified in a comprehensive movement disorder cohort from two different neurological centers, comprising a total of 171 CSF samples. Commercially available ELISA systems were employed for quantification.The results of the MBP analysis revealed a significant increase in cerebrospinal fluid (CSF) MBP levels in all atypical Parkinsonian conditions compared to PD. This differentiation was more pronounced in the MSA-c subtype compared to MSA-p. Receiver operating characteristic (ROC) analysis revealed a significant discrimination between PD and MSA (p = 0.032, AUC = 0.70), PD and DLB (p = 0.006, AUC = 0.79) and PD and tauopathies (p = 0.006, AUC = 0.74). The results of the TREM2 analysis demonstrated no significant differences between the PD and atypical Parkinsonian groups if not adjusted for confounders. After adjusting for age, sex, and disease duration, the PD group exhibited significantly higher TREM2 levels compared to the DLB group (p = 0.002).In conclusion, MBP, but not TREM2, is elevated in the CSF of not only MSA but in all atypical Parkinsonian conditions compared to idiopathic Parkinson's disease. This highlights the value of the evaluation of myelin/oligodendrocyte-associated markers in neurodegenerative movement disorders.
KW  - Humans
KW  - Multiple System Atrophy: cerebrospinal fluid
KW  - Multiple System Atrophy: diagnosis
KW  - Female
KW  - Male
KW  - Aged
KW  - Membrane Glycoproteins: cerebrospinal fluid
KW  - Middle Aged
KW  - Receptors, Immunologic
KW  - Biomarkers: cerebrospinal fluid
KW  - Myelin Basic Protein: cerebrospinal fluid
KW  - Parkinsonian Disorders: cerebrospinal fluid
KW  - Parkinsonian Disorders: diagnosis
KW  - Parkinson Disease: cerebrospinal fluid
KW  - Parkinson Disease: diagnosis
KW  - Cohort Studies
KW  - Aged, 80 and over
KW  - Biomarker (Other)
KW  - Cerebrospinal fluid (Other)
KW  - Multiple system atrophy (Other)
KW  - Myelin basic protein (Other)
KW  - TREM2 (Other)
KW  - TREM2 protein, human (NLM Chemicals)
KW  - Membrane Glycoproteins (NLM Chemicals)
KW  - Receptors, Immunologic (NLM Chemicals)
KW  - Biomarkers (NLM Chemicals)
KW  - Myelin Basic Protein (NLM Chemicals)
KW  - MBP protein, human (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C2  - pmc:PMC11638341
C6  - pmid:39666067
DO  - DOI:10.1007/s00415-024-12747-w
UR  - https://pub.dzne.de/record/273938
ER  -